Wells Fargo raised the firm’s price target on NeuroPace (NPCE) to $17 from $13 and keeps an Overweight rating on the shares. The firm notes NeuroPace laid out its strategy and LRP at its investor day on January 28. Wells views its new multiple as appropriate given solid management execution and recent beat and raises.